Embecta beats, ups guidance despite U.S. revenue pressure

 

Embecta beats Q3 2026 estimates and raises EPS and margin guidance despite U.S. revenue pressure

• Q3 2026 non-GAAP EPS $0.56, down 50% YoY, but ahead of analyst estimates.
• Q3 revenue $272 million, down 8% YoY, but strong sequential rebound.
• U.S. revenue down 24.6% YoY on pricing, mix, and insulin pen weakness.
• International revenue up 9.7% constant currency, led by Latin America and Asia.
• Adjusted gross margin fell to 58.2% from 67.2% on lower U.S. volume.
• Raised FY26 adjusted operating margin guidance to 23.5–24% on cost optimizations.
• Raised FY26 adjusted EPS outlook to $1.80–$1.90, reaffirmed revenue guidance range.
• Closed Owen Mumford acquisition; early contribution aided revenue and supports auto-injector expansion.
• Deleveraging continues with $53 million debt repaid and $41 million free cash flow.
• Management sees stable U.S. share but monitors ACA, Medicaid, and GLP-1 impacts.
• Investors focused on U.S. recovery durability and timing of Aidaptus auto-injector ramp.
• Main concern: Persistent U.S. volume and pricing pressure amid GLP-1 adoption and payer shifts.
• Mixed quarter, driven by international strength, cost controls, and ongoing U.S. softness.

https://finviz.com/stock?t=EMBC&p=d